(19)
(11) EP 2 938 325 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
25.09.2019 Bulletin 2019/39

(45) Mention of the grant of the patent:
10.04.2019 Bulletin 2019/15

(21) Application number: 13830158.5

(22) Date of filing: 27.12.2013
(51) International Patent Classification (IPC): 
A61K 9/08(2006.01)
A61K 31/196(2006.01)
 A61K 47/10(2017.01)
A61P 29/00(2006.01)
(86) International application number:
PCT/IN2013/000805
(87) International publication number:
WO 2014/102824 (03.07.2014 Gazette 2014/27)

(54)

DICLOFENAC COMPOSITION

DICLOFENACZUSAMMENSETZUNG

COMPOSITION DE DICLOFÉNAC

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30) Priority: 28.12.2012 IN 3704MU2012

(43) Date of publication of application:
04.11.2015 Bulletin 2015/45

(73) Proprietor: Themis Medicare Limited
Goregaon (W), Mumbai 400 104 (IN)

(72) Inventors:
  • PATEL, Dinesh Shantilal
    Mumbai 400 104 Maharashtra (IN)
  • PATEL, Sachin Dinesh
    Mumbai 400 104 Maharashtra (IN)
  • KURANI, Shashikant Prabhudas
    Mumbai 400 104 Maharashtra (IN)
  • PATEL, Madhavlal Govindlal
    Mumbai 400 104 Maharashtra (IN)

(74) Representative: HGF Limited 
1 City Walk
Leeds LS11 9DX
Leeds LS11 9DX (GB)


(56) References cited: : 
WO-A2-2005/027977
US-A1- 2008 153 914
 WO-A2-2006/126214
   
  • M. MANCONI ET AL: "Penetration enhancer-containing vesicles: Composition dependence of structural features and skin penetration ability", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, vol. 82, no. 2, 1 October 2012 (2012-10-01), pages 352-359, XP055115170, ISSN: 0939-6411, DOI: 10.1016/j.ejpb.2012.06.015
  • "Final Report - Measurement of Pain Sensitivity (Threshold) at Aquadol Injection Site in Wistar Rats by Intramuscular Route", 25 June 2014 (2014-06-25), Spira Labs Limited
  • NICOLL LESLIE H ET AL: "Intramuscular injection: an integrative research review and guideline for evidence-based practice.", APPLIED NURSING RESEARCH : ANR AUG 2002, vol. 15, no. 3, August 2002 (2002-08), pages 149-162, ISSN: 0897-1897
  • "Propylene Glycol" In: "Handbook of Pharmaceutical Excipients", 2009 pages 592-594,
  • "Polyethylene Glycol" In: "Handbook of Pharmaceutical Excipients", 2009 pages 517-522,
  • Aparacio RM et al.: "In vitro studies of the hemolytic activity of microemulsions in human erythrocytes", ScienceDirect Journal of Pharmaceutical and Biomedical Analysis, vol. 39, no. 5 28 July 2005 (2005-07-28), Retrieved from the Internet: URL:http://www.sciencedirect.com/science/a rticle/pii/S0731708505004139 [retrieved on 2016-06-17]
  • Mottu F et al.: "Comparative Hemolytic Activity of Undiluted Organic Water-Miscible Solvents for Intravenous and Intra-Arterial Injection", journal.pda.org PDA Journal of Pharmaceutical Science and Technology, vol. 55, no. 1 2001, Retrieved from the Internet: URL:http://journal.pda.org/content/55/1/16 .abstract?ijkey=e8b62278383a2566ddc69d24ac 9947b6f94e92bb&keytype2=tf_ipsecsha [retrieved on 2016-06-20]
  • "Glycofurol" In: "Handbook of Pharmaceutical Excipients", 2009 pages 297-298,
 
Remarks:
The file contains technical information submitted after the application was filed and not included in this specification
 
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).